Latest news with #STAARSurgical
Associated Press
07-08-2025
- Business
- Associated Press
STAAR SURGICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of STAAR Surgical Company
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Aug 7, 2025-- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed sale of STAAR Surgical Company (NasdaqGM: STAA) to Alcon Inc. (NYSE: ALC). Under the terms of the proposed transaction, shareholders of STAAR will receive $28.00 in cash for each share of STAAR that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( [email protected] ) toll free at any time at 855-768-1857, or visit to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn View source version on CONTACT: Lewis S. Kahn, 855-768-1857 KSF Managing Partner [email protected] Swick & Foti, LLC 1100 Poydras St., Suite 960 New Orleans, LA 70163 KEYWORD: UNITED STATES NORTH AMERICA LOUISIANA NEW YORK INDUSTRY KEYWORD: CLASS ACTION LAWSUIT PROFESSIONAL SERVICES LEGAL SOURCE: Kahn Swick & Foti, LLC Copyright Business Wire 2025. PUB: 08/07/2025 11:39 AM/DISC: 08/07/2025 11:38 AM
Yahoo
07-08-2025
- Business
- Yahoo
STAAR Surgical (NASDAQ:STAA) Delivers Strong Q2 Numbers
Medical lens company STAAR Surgical (NASDAQ:STAA) announced better-than-expected revenue in Q2 CY2025, but sales fell by 55.2% year on year to $44.32 million. Its GAAP loss of $0.34 per share was 49.9% above analysts' consensus estimates. Is now the time to buy STAAR Surgical? Find out in our full research report. STAAR Surgical (STAA) Q2 CY2025 Highlights: Revenue: $44.32 million vs analyst estimates of $40.45 million (55.2% year-on-year decline, 9.6% beat) EPS (GAAP): -$0.34 vs analyst estimates of -$0.68 (49.9% beat) Adjusted EBITDA: -$14.94 million vs analyst estimates of -$24.95 million (-33.7% margin, 40.1% beat) Operating Margin: -67.6%, down from 12% in the same quarter last year Free Cash Flow was -$29.04 million compared to -$16.65 million in the same quarter last year Market Capitalization: $1.32 billion Company Overview With over 2.5 million implants performed worldwide, STAAR Surgical (NASDAQ:STAA) designs and manufactures implantable lenses that correct vision problems without removing the eye's natural lens. Revenue Growth A company's long-term performance is an indicator of its overall quality. Any business can put up a good quarter or two, but many enduring ones grow for years. Thankfully, STAAR Surgical's 8.6% annualized revenue growth over the last five years was decent. Its growth was slightly above the average healthcare company and shows its offerings resonate with customers. We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. STAAR Surgical's recent performance marks a sharp pivot from its five-year trend as its revenue has shown annualized declines of 14.3% over the last two years. This quarter, STAAR Surgical's revenue fell by 55.2% year on year to $44.32 million but beat Wall Street's estimates by 9.6%. Looking ahead, sell-side analysts expect revenue to grow 44.4% over the next 12 months, an improvement versus the last two years. This projection is eye-popping and suggests its newer products and services will spur better top-line performance. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. Adjusted Operating Margin STAAR Surgical was profitable over the last five years but held back by its large cost base. Its average adjusted operating margin of 1.1% was weak for a healthcare business. Analyzing the trend in its profitability, STAAR Surgical's adjusted operating margin decreased by 62 percentage points over the last five years. The company's two-year trajectory also shows it failed to get its profitability back to the peak as its margin fell by 57.3 percentage points. This performance was poor no matter how you look at it - it shows its expenses were rising and it couldn't pass those costs onto its customers. This quarter, STAAR Surgical generated an adjusted operating margin profit margin of negative 67.6%, down 79.6 percentage points year on year. This contraction shows it was less efficient because its expenses increased relative to its revenue. Earnings Per Share Revenue trends explain a company's historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth – for example, a company could inflate its sales through excessive spending on advertising and promotions. Sadly for STAAR Surgical, its EPS declined by 70.2% annually over the last five years while its revenue grew by 8.6%. This tells us the company became less profitable on a per-share basis as it expanded. We can take a deeper look into STAAR Surgical's earnings to better understand the drivers of its performance. As we mentioned earlier, STAAR Surgical's adjusted operating margin declined by 62 percentage points over the last five years. Its share count also grew by 9.2%, meaning the company not only became less efficient with its operating expenses but also diluted its shareholders. In Q2, STAAR Surgical reported EPS at negative $0.34, down from $0.15 in the same quarter last year. Despite falling year on year, this print easily cleared analysts' estimates. Over the next 12 months, Wall Street is optimistic. Analysts forecast STAAR Surgical's full-year EPS of negative $1.93 will reach break even. Key Takeaways from STAAR Surgical's Q2 Results We were impressed by how significantly STAAR Surgical blew past analysts' EPS expectations this quarter. We were also excited its revenue outperformed Wall Street's estimates by a wide margin. Zooming out, we think this was a solid print. The stock remained flat at $26.85 immediately after reporting. So should you invest in STAAR Surgical right now? What happened in the latest quarter matters, but not as much as longer-term business quality and valuation, when deciding whether to invest in this stock. We cover that in our actionable full research report which you can read here, it's free.
Yahoo
06-08-2025
- Business
- Yahoo
Alcon Strikes $1.5 Billion Deal to Acquire STAAR Surgical
Alcon (ALC) on Tuesday agreed to acquire eye lens manufacturer STAAR Surgical (STAA) in a deal worth Sign in to access your portfolio
Yahoo
06-08-2025
- Business
- Yahoo
Why Are STAAR Surgical (STAA) Shares Soaring Today
What Happened? Shares of medical lens company STAAR Surgical (NASDAQ:STAA) jumped 45.6% in the afternoon session after eye-care company Alcon announced a definitive agreement to acquire the company in an all-cash deal valued at approximately $1.5 billion. Under the terms of the deal, Alcon paid $28 in cash for each share of STAAR Surgical. This price marked a 51% premium to the company's closing stock price on the previous day. STAAR Surgical manufactured implantable lenses for vision correction, including its EVO family of Implantable Collamer® Lenses. The acquisition allowed Alcon to absorb a key player in the ophthalmic surgery space. Is now the time to buy STAAR Surgical? Access our full analysis report here, it's free. What Is The Market Telling Us STAAR Surgical's shares are very volatile and have had 29 moves greater than 5% over the last year. But moves this big are rare even for STAAR Surgical and indicate this news significantly impacted the market's perception of the business. The previous big move we wrote about was 7 days ago when the stock dropped 3.2% on the news that industry bellwether UnitedHealth Group (UNH) slashed its 2025 profit forecast after reporting a significant surge in medical costs, sending shockwaves across the health insurance sector. The core of the issue stems from an 'unprecedented medical cost trend environment,' particularly within the Medicare Advantage market, which are privately run versions of the federal health insurance program. UnitedHealth, the largest provider in this space, now expects these costs to rise by 7.5% in 2025, a significant jump from its earlier 5% projection, with the potential to accelerate to almost 10% in 2026. In response, the insurer announced it will drop plans covering over 600,000 people. The company's lowered earnings forecast has raised investor concerns that these surging costs and utilization rates are an industry-wide problem, impacting the profitability of other carriers as well. STAAR Surgical is up 12.2% since the beginning of the year, but at $27.04 per share, it is still trading 33% below its 52-week high of $40.36 from August 2024. Investors who bought $1,000 worth of STAAR Surgical's shares 5 years ago would now be looking at an investment worth $437.39. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Melden Sie sich an, um Ihr Portfolio aufzurufen.
Yahoo
05-08-2025
- Business
- Yahoo
Alcon Expands Vision Correction Portfolio With STAAR Surgical Acquisition
On Tuesday, the eye care company Alcon Plc (NYSE:ALC) agreed to acquire STAAR Surgical Company (NASDAQ:STAA), the manufacturer of the implantable collamer lens (ICL). The acquisition includes the EVO family of lenses (EVO ICL) for vision correction for patients with moderate to high myopia (nearsightedness), with or without astigmatism. Alcon will purchase all outstanding shares of STAAR common stock for $28 per share in cash, which represents approximately a 59% premium to STAAR's 90-day Volume Weighted Average Price (VWAP) and a 51% premium to the closing price of STAAR common stock on August 4, transaction represents a total equity value of approximately $1.5 billion. Alcon intends to finance the transaction by issuing short- and long-term credit facilities. The transaction is anticipated to close in approximately six to 12 months and is expected to be accretive to earnings in year two. 'With the number of high myopes rising globally, the acquisition of STAAR enhances our ability to offer a leading surgical vision correction solution for those who are not ideal candidates for other refractive surgeries such as LASIK,' said David Endicott, CEO of Alcon. An estimated 50% of the world will be myopic by 2050, and today, nearly 500 million people are considered high myopes. The EVO family of ICLs are implanted between the iris (the colored part of the eye) and the natural crystalline lens during a procedure that does not remove corneal tissue. This move follows Alcon's recent announcement in July regarding its intention to acquire LumiThera, Inc. and its Photobiomodulation (PBM) Device for dry age-related macular degeneration (AMD). Data from the LIGHTSITE I, II, and III clinical trials consistently showed that PBM treatments provide visual acuity improvement with no treatment-related serious adverse events reported. PBM received FDA de novo market authorization in November 2024 and CE Mark in November 2018. PBM is available in Europe, Latin America, Singapore, the U.K., and the U.S. The transaction does not include the acquisition of AdaptDx and Nova/Diopsys diagnostic devices, which will be separated and spun off to LumiThera's shareholders before Alcon's acquisition and will continue to be marketed and sold by the LumiThera spin-off. Alcon and LumiThera anticipate the acquisition to be completed in the third quarter of 2025. Price Action: ALC stock is trading lower by 1.17% to $86.79 premarket, and STAA stock is trading higher by 44.9% to $26.78 at last check Tuesday. Read Next:Photo via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? STAAR SURGICAL (STAA): Free Stock Analysis Report This article Alcon Expands Vision Correction Portfolio With STAAR Surgical Acquisition originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
